Johnson & Johnson Stock (JNJ) After Hours Today (Dec. 18, 2025): FDA Approvals, Analyst Targets, and Talc Litigation in Focus Ahead of Friday’s Open
Johnson & Johnson (NYSE: JNJ) finished Thursday’s regular session lower even as the broader market moved higher, then ticked modestly upward in after-hours trading—leaving investors with a familiar year-end setup: solid pipeline/MedTech progress on one side, and talc litigation headlines
